Apimeds Pharmaceuticals US, Inc. (APUS) Form 8-K — Aug 21, 2026

$APUSForm 8-KItems 1.01, 9.01Filed Aug 21, 2026, 5:12 PM ET0001213900-26-092680Original filing

On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement of Certain Apitox Rights with FreeT Inc. of South Korea, under which FreeT irrevocably assigned to the company all of its right, title and interest in Apitox-related rights originally acquired by CNP Roen Co., Ltd. under a 2015 agreement.

Key figures

Korean clinic market rights: 100%
Us commercialization royalty: 25%
Original rights agreement date: 2015-06-16
Overseas revenue participation: 25%

Price after filing

1 day: 0.0%7 days: -20.0%30 days: -63.4%

Close on the filing date to close N calendar days later (from $4.84). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.